User
Favorite list
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
February 16–18, 2021
Meet us online at the CAR-TCR Digital Summit Europe.
Bringing together large pharma, biotech, academia, and regulatory boards, the CAR-TCR Digital Summit Europe is the definite platform to network, share ideas, and take part in sessions to advance novel cell products and overcome bottlenecks in developing CAR-TCR therapies. Join the European community of CAR and TCR drug developers and hear lessons learned to move your own pipeline towards clinical and commercial success.
Don’t miss out on our talk ”Challenges and solutions for GMP-compliant CAR T cell manufacturing” and visit us in the virtual exhibit hall to learn how to harness closed system automation for the manufacturing of CAR T cells. Schedule a meeting with us within the virtual booth and see how we can support your vision in commercial-scale cell manufacturing.
The presentation reveals approaches to shorten needle-to-needle time while maintaining high intention-to-treat. Furthermore, we take a deeper look at the challenges around quality control (QC) and how closed, automated systems can help design new strategies. Last but not least, solutions towards increased gene-engineering complexity and their opportunities will be explained.
Senior Manager R&D Cell & Gene Immunotherapy / Clinical Process Development, Miltenyi Biotec
Dr. Andrew Kaiser is a translational immunologist with a strong focus on the development of cell and gene immunotherapies against cancer and nearly 20 years experience in both academia and industry. He joined Miltenyi Biotec’s R&D in 2012, where he is now Senior Manager and leads several teams focusing on the implementation of effective cell and gene therapies. Efforts are more specifically driven towards developing tools and technologies for clinical applications of adoptive cell therapy through the automation of gene-modified T cell manufacturing; designing innovative molecular technologies to improve the clinical outcome of CAR T cells therapies; and bringing novel drugs to the clinic.
Copyright © 2021 Miltenyi Biotec and/or its affiliates. All rights reserved.
